210 related articles for article (PubMed ID: 29936123)
1. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood mononuclear cells preferentially activate 11-oxygenated androgens.
Schiffer L; Bossey A; Kempegowda P; Taylor AE; Akerman I; Scheel-Toellner D; Storbeck KH; Arlt W
Eur J Endocrinol; 2021 Mar; 184(3):353-363. PubMed ID: 33444228
[TBL] [Abstract][Full Text] [Related]
4. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
5. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
[TBL] [Abstract][Full Text] [Related]
6. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.
Chen J; Yang Y; Xu D; Li J; Wu S; Jiang Y; Wang C; Yang Z; Zhao L
Biochem Biophys Res Commun; 2021 Feb; 540():83-89. PubMed ID: 33450484
[TBL] [Abstract][Full Text] [Related]
8. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
12. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
13. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling.
Gu Y; Wu S; Chong Y; Guan B; Li L; He D; Wang X; Wang B; Wu K
Cell Signal; 2022 Jul; 95():110336. PubMed ID: 35452821
[TBL] [Abstract][Full Text] [Related]
14. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
16. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
18. ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.
Migita T; Takayama KI; Urano T; Obinata D; Ikeda K; Soga T; Takahashi S; Inoue S
Cancer Sci; 2017 Oct; 108(10):2011-2021. PubMed ID: 28771887
[TBL] [Abstract][Full Text] [Related]
19. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
20. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
